Who
Lenaic Nathanael Teyssedou
Principal Accounting Officer
Company insider
Files Form 4 as: Principal Accounting Officer, Addex Therapeutics.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Sep 2026
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —37,770 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,620 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —90,529 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,529 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —208,974 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —208,974 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,485 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,485 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,770 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —59,530 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —37,770 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,770 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —59,530 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,530 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —65,620 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,620 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.